PMID: 3395611May 1, 1988Paper

Dietary menhaden oil: effects on the rate and magnitude of modification of phospholipid fatty acid composition of mouse heart and brain

The British Journal of Nutrition
J E SwansonJ E Kinsella

Abstract

1. Male CD-1 white mice, 18-20 g body-weight, were given semi-purified diets containing 100 g menhaden oil (MO) or hydrogenated coconut oil (HCO)/kg for 23 d. Mice were killed on days 0, 3, 5, 7, 14, 23. After 23 d of MO supplementation the remaining mice were switched to the HCO diet for an additional 10 d. 2. The progressive change(s) in the polyunsaturated fatty acid (PUFA) composition of cardiac and brain phospholipid classes were followed during the MO supplementation and depletion periods. 3. The content of fatty acids 20:5n-3, 22:5n-3 and 22:6n-3 increased immediately following ingestion of the MO diet and continued to increase at a steady rate in both heart and brain phospholipid classes. 4. In general, the period required to reach steady-state was 1 week for n-3 PUFA and 18:2n-6, and 2 weeks for 20:4n-6. 5. Cessation of MO consumption for 10 d resulted in marked decreases in the content of n-3 PUFA and increases in n-6 PUFA in cardiac phospholipids in particular. Brain phospholipids were less responsive. 6. The results suggest that dietary fish oil must be consumed for at least 1 week before maximum changes in PUFA composition are observed, and fish oil ingestion must be continuous to maintain elevated n-3 PUFA levels ...Continue Reading

References

Jan 1, 1978·Advances in Cardiology·S GudbjarnasonJ Hallgrímsson
Dec 1, 1985·The Journal of Clinical Investigation·C von Schacky, P C Weber
Sep 1, 1985·The Proceedings of the Nutrition Society·T A Sanders

❮ Previous
Next ❯

Citations

Mar 1, 1990·The Journal of Nutritional Biochemistry·J E KinsellaJ W Whelan
Aug 2, 2012·Cancer Treatment Reviews·Nawale Hajjaji, Philippe Bougnoux
Sep 1, 1991·Prostaglandins, Leukotrienes, and Essential Fatty Acids·M A BeluryS M Fischer
Aug 12, 2009·Lipids in Health and Disease·Breanne M Anderson, David W L Ma
May 16, 2008·Cancer Letters·Isabelle M BerquinYong Q Chen
Dec 20, 2011·American Journal of Physiology. Heart and Circulatory Physiology·Moni NaderBalwant S Tuana
Jan 1, 1991·Progress in Lipid Research·S M Innis
Jan 1, 1992·Neuroscience and Biobehavioral Reviews·P E Wainwright

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.